Will precision medicine move us beyond race?

New England Journal of Medicine

Volumn 374, Issue 21, 2016, Pages 2003-2005

  Bonham, Vence L ^a   Callier, Shawneequa L ^b   Royal, Charmaine D ^c  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANCESTRY GROUP; DRUG APPROVAL; DRUG THERAPY; FOOD AND DRUG ADMINISTRATION; GENETICS; HUMAN; PERSONALIZED MEDICINE; UNITED STATES;

CONTINENTAL POPULATION GROUPS; DRUG APPROVAL; DRUG THERAPY; HUMANS; PRECISION MEDICINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84971330874     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1511294     Document Type: Review

References (5)

1. Temple R, Stockbridge NL. BiDil for heart failure in black patients: The U.S. Food and Drug Administration perspective. Ann Intern Med 2007; 146: 57-62.
2. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-20.
3. Wu AHB, WhiteSam Oh MJ, Burchard E. The Hawaii clopidogrel lawsuit: the possible effect on clinical laboratory testing. Personalized Medicine 2015; 12: 179-81.
4. Ramamoorthy A, Pacanowski MA, Bull J, Zhang L. Racial/ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther 2015; 97: 263-73.
5. The Precision Medicine Initiative (PMI) Working Group. The Precision Medicine Initiative Cohort Program-building a research foundation for 21st century medicine. Bethesda, MD: National Institutes of Health, 2015 (http://www.nih.gov/precisionmedicine/09172015-pmi-working-group-report.pdf).